S&P 500   4,769.83
DOW   37,689.54
QQQ   409.52
US Navy helicopters fire at Yemen's Houthi rebels and kill several in latest Red Sea shipping attack
New Year's Sale: Get MarketBeat All Access Free For 30 Days (Ad)
A lithium-ion battery fire in a cargo ship's hold is out after several days of burning
Chief Justice Roberts casts a wary eye on the uses of artificial intelligence in the federal courts
New Year's Sale: Get MarketBeat All Access Free For 30 Days (Ad)
S&P 500   4,769.83
DOW   37,689.54
QQQ   409.52
US Navy helicopters fire at Yemen's Houthi rebels and kill several in latest Red Sea shipping attack
New Year's Sale: Get MarketBeat All Access Free For 30 Days (Ad)
A lithium-ion battery fire in a cargo ship's hold is out after several days of burning
Chief Justice Roberts casts a wary eye on the uses of artificial intelligence in the federal courts
New Year's Sale: Get MarketBeat All Access Free For 30 Days (Ad)
S&P 500   4,769.83
DOW   37,689.54
QQQ   409.52
US Navy helicopters fire at Yemen's Houthi rebels and kill several in latest Red Sea shipping attack
New Year's Sale: Get MarketBeat All Access Free For 30 Days (Ad)
A lithium-ion battery fire in a cargo ship's hold is out after several days of burning
Chief Justice Roberts casts a wary eye on the uses of artificial intelligence in the federal courts
New Year's Sale: Get MarketBeat All Access Free For 30 Days (Ad)
S&P 500   4,769.83
DOW   37,689.54
QQQ   409.52
US Navy helicopters fire at Yemen's Houthi rebels and kill several in latest Red Sea shipping attack
New Year's Sale: Get MarketBeat All Access Free For 30 Days (Ad)
A lithium-ion battery fire in a cargo ship's hold is out after several days of burning
Chief Justice Roberts casts a wary eye on the uses of artificial intelligence in the federal courts
New Year's Sale: Get MarketBeat All Access Free For 30 Days (Ad)
NASDAQ:ZVSA

ZyVersa Therapeutics (ZVSA) Stock Price, News & Analysis

$0.90
-0.05 (-5.26%)
(As of 12/29/2023 ET)
Today's Range
$0.86
$0.99
50-Day Range
$0.71
$4.12
52-Week Range
$0.68
$153.30
Volume
274,168 shs
Average Volume
1.51 million shs
Market Capitalization
$1.12 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$87.50

ZyVersa Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
9,622.2% Upside
$87.50 Price Target
Short Interest
Healthy
0.36% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.62mentions of ZyVersa Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($138.81) to ($10.77) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.12 out of 5 stars


ZVSA stock logo

About ZyVersa Therapeutics Stock (NASDAQ:ZVSA)

ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company engages in the development of VAR 200, a cholesterol efflux mediator, which is in Phase 2a clinical trial to the treatment of multiple renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic nephropathy; and IC 100, a monoclonal antibody inflammasome ASC inhibitor that is in preclinical stage for treatment of multitude of inflammatory diseases. ZyVersa Therapeutics, Inc. is headquartered in Weston, Florida.

ZVSA Stock Price History

ZVSA Stock News Headlines

New Year's Sale: Get MarketBeat All Access Free For 30 Days
Access our premier research platform that includes MarketBeat Daily Premium, portfolio monitoring tools, stock screeners, research tools, a real-time news feed, email and SMS alerts, the MarketBeat Idea Engine, proprietary brokerage rankings, extended data export tools and much more. Click the link to claim your $300.00 account credit and free 30-day subscription
Claim Your $300 MarketBeat Account Credit
Click the link below to claim your $300.00 account credit toward MarketBeat All Access. Pay just $99.00 for your 2024 MarketBeat All Access subscription (normally $399.00)
ZyVersa Therapeutics, Inc. (ZVSA)
Why Is Cerevel Therapeutics (CERE) Stock Up 12% Today?
Why ZyVersa Therapeutics Shares Are Down 40%
Why Is ZyVersa Therapeutics (ZVSA) Stock Up 27% Today?
ZyVersa Therapeutics Inc ZVSA
See More Headlines
Receive ZVSA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ZyVersa Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/14/2023
Today
12/31/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/13/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ZVSA
Fax
N/A
Employees
7
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$87.50
High Stock Price Target
$87.50
Low Stock Price Target
$87.50
Potential Upside/Downside
+9,622.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-14,120,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$386.50 per share

Miscellaneous

Free Float
1,184,000
Market Cap
$1.12 million
Optionable
Not Optionable
Beta
0.27
The Best High-Yield Dividend Stocks for 2023 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Mr. Stephen C. Glover (Age 63)
    Co-Founder, Chairman, CEO & President
    Comp: $450.5k
  • Mr. Peter Wolfe (Age 55)
    CFO & Secretary
    Comp: $275k
  • Ms. Karen A. Cashmere (Age 71)
    Chief Commercial Officer
    Comp: $300k
  • Ms. Melda Uzbil O'connell
    Senior Vice President of Corporate Development
  • Dr. Pablo A. Guzman FACC (Age 73)
    M.D., Chief Medical Officer, Senior VP of Medical Affairs & Chairman of Renal Scientific Advisory Board














ZVSA Stock Analysis - Frequently Asked Questions

Should I buy or sell ZyVersa Therapeutics stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ZyVersa Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ZVSA shares.
View ZVSA analyst ratings
or view top-rated stocks.

What is ZyVersa Therapeutics' stock price target for 2024?

1 analysts have issued 1 year target prices for ZyVersa Therapeutics' shares. Their ZVSA share price targets range from $87.50 to $87.50. On average, they expect the company's stock price to reach $87.50 in the next twelve months. This suggests a possible upside of 9,622.2% from the stock's current price.
View analysts price targets for ZVSA
or view top-rated stocks among Wall Street analysts.

How have ZVSA shares performed in 2023?

ZyVersa Therapeutics' stock was trading at $54.95 at the beginning of 2023. Since then, ZVSA stock has decreased by 98.4% and is now trading at $0.90.
View the best growth stocks for 2023 here
.

When is ZyVersa Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 13th 2024.
View our ZVSA earnings forecast
.

How were ZyVersa Therapeutics' earnings last quarter?

ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) issued its earnings results on Tuesday, November, 14th. The company reported ($3.15) earnings per share for the quarter, beating the consensus estimate of ($5.60) by $2.45.

When did ZyVersa Therapeutics' stock split?

ZyVersa Therapeutics's stock reverse split on the morning of Tuesday, December 5th 2023. The 1-35 reverse split was announced on Tuesday, December 5th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, December 5th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

How do I buy shares of ZyVersa Therapeutics?

Shares of ZVSA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ZVSA) was last updated on 12/31/2023 by MarketBeat.com Staff

My Account -